These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32436682)

  • 1. Economic burden of osteoporotic fractures in US managed care enrollees.
    Williams SA; Chastek B; Sundquist K; Barrera-Sierra S; Leader D; Weiss RJ; Wang Y; Curtis JR
    Am J Manag Care; 2020 May; 26(5):e142-e149. PubMed ID: 32436682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy.
    Viswanathan HN; Curtis JR; Yu J; White J; Stolshek BS; Merinar C; Balasubramanian A; Kallich JD; Adams JL; Wade SW
    Appl Health Econ Health Policy; 2012 May; 10(3):163-73. PubMed ID: 22510025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
    Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
    J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and Treatment of Osteoporosis Before and After Fracture: A Side-by-Side Analysis of Commercially Insured and Medicare Advantage Osteoporosis Patients.
    Weaver J; Sajjan S; Lewiecki EM; Harris ST
    J Manag Care Spec Pharm; 2017 Jul; 23(7):735-744. PubMed ID: 28650253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture.
    Weaver J; Sajjan S; Lewiecki EM; Harris ST; Marvos P
    J Manag Care Spec Pharm; 2017 Apr; 23(4):461-471. PubMed ID: 28345441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
    Margolis J; Barron JJ; Grochulski WD
    J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
    Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
    J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
    Bhowmik D; Hines DM; Intorcia M; Wade RL
    J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of fractures commonly associated with osteoporosis in a managed-care population.
    Christensen L; Iqbal S; Macarios D; Badamgarav E; Harley C
    J Med Econ; 2010; 13(2):302-13. PubMed ID: 20482324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Burden of Osteoporosis-Related Fractures in the US Medicare Population.
    Williams SA; Daigle SG; Weiss R; Wang Y; Arora T; Curtis JR
    Ann Pharmacother; 2021 Jul; 55(7):821-829. PubMed ID: 33148010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants.
    Watson C; Xu H; Princic N; Sruti I; Barlev A
    J Med Econ; 2020 Oct; 23(10):1159-1167. PubMed ID: 32643493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.
    Schultz NM; Penson DF; Wilson SD; Song Y; Yang H; Ramaswamy K; Lowentritt B
    J Manag Care Spec Pharm; 2019 Aug; 25(8):889-897. PubMed ID: 31172866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare Resource Utilization and Direct Medical Costs for Patients With Osteoporotic Fractures in China.
    Wu J; Qu Y; Wang K; Chen Y
    Value Health Reg Issues; 2019 May; 18():106-111. PubMed ID: 30909083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of Osteoporotic Fractures in Singapore.
    Ng CS; Lau TC; Ko Y
    Value Health Reg Issues; 2017 May; 12():27-35. PubMed ID: 28648313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy.
    Modi A; Siris ES; Tang J; Sen S
    Curr Med Res Opin; 2015 Apr; 31(4):757-65. PubMed ID: 25661017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical and economic burden of newly diagnosed Alzheimer's disease in a medicare advantage population.
    Suehs BT; Davis CD; Alvir J; van Amerongen D; Pharmd NC; Joshi AV; Faison WE; Shah SN
    Am J Alzheimers Dis Other Demen; 2013 Jun; 28(4):384-92. PubMed ID: 23687180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-related and all-cause health care costs of elderly patients with gout.
    Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
    J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical Costs for Osteoporosis-Related Fractures in High-Risk Medicare Beneficiaries.
    Kapinos KA; Fischer SH; Mulcahy A; Hayden O; Barron R
    J Am Geriatr Soc; 2018 Dec; 66(12):2298-2304. PubMed ID: 30289961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE; Yu J; Campbell HE; Abarca J; White TJ
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
    Kearney M; Thokagevistk K; Boutmy E; Bharmal M
    J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.